Skip NavigationSkip to Content

Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles

  1. Author:
    Trubey, C. M.
    Chertova, E.
    Coren, L. V.
    Hilburn, J. M.
    Hixson, C. V.
    Nagashima, K.
    Lifson, J. D.
    Ott, D. E.
  2. Author Address

    NCI, SAIC Frederick Inc, Basic Res Program, Frederick, MD 21702 USA NCI, SAIC Frederick Inc, Basic Res Program, Frederick, MD 21702 USA NCI, SAIC Frederick Inc, Res Technol Program, Frederick, MD 21702 USA Ott DE NCI, SAIC Frederick Inc, Basic Res Program, Frederick, MD 21702 USA
    1. Year: 2003
  1. Journal: Journal of Virology
    1. 77
    2. 23
    3. Pages: 12699-12709
  2. Type of Article: Article
  1. Abstract:

    Among the many host cell-derived proteins found in human immunodeficiency virus type 1 (HIV-1), HLA class 11 (HLA-II) appears to be selectively incorporated onto virions and may contribute to mechanisms of indirect imunopathogenesis in HIV infection and AIDS. However, the amount of HLA-II on the surface of HIV-1 particles has not been reliably determined due to contamination of virus preparations by microvesicles containing host cell proteins, including HLA-II. Even rigorous sucrose density centrifugation is unable to completely separate HIV-1 from microvesicles. CD45, a leukocyte integral membrane protein, is found on microvesicles, yet appears to be excluded from HIV-1 particles. Exploiting this observation, we have developed a CD45-based immunoaffinity depletion method for removing CD45-containing microvesicles that yields highly purified preparations of virions. Examination of CD45-depleted HIV-1(MN) by high-pressure liquid chromatography, protein sequencing, and amino acid analyses determined a molar ratio of HLA-II to Gag of 0.04 to 0.05 in the purified virions, corresponding to an estimated average of 50 to 63 native HLA-II complexes (i.e., a dimer of alpha and beta heterodimers) per virion. These values are approximately 5- to 10-fold lower than those previously determined for other virion preparations that contained microvesicles. Our observations demonstrate the utility of CD45 immunoaffinity-based approaches for producing highly purified retrovirus preparations for applications that would benefit from the use of virus that is essentially free of microvesicles.

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel